Morgan Stanley Global Healthcare Conference | AI, China and the Future of Biotech

Watch on YouTube ↗  |  September 16, 2026 at 19:00  |  1:05  |  Morgan Stanley
Speakers
Sean Laaman — Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley

Summary

Sean Laaman, Head of U.S. Mid-Cap Biotech Equity Research at Morgan Stanley, summarizes key themes from the 24th Annual Morgan Stanley Global Healthcare Conference. He highlights AI as a transformative force in drug development, China's evolution from fast follower to genuine biotech innovator, and expectations for faster drug approvals as regulators seek to keep pace with China. The video frames these as the most debated topics in biotechnology.

  • Conference debate centered on AI in drug development, China innovation, and regulation.
  • Morgan Stanley sees AI changing drug development with better drugs and faster timelines.
  • China is described as extremely dynamic and a genuine biotech innovator.
  • There is debate over whether China has taken innovation leadership from the U.S.
  • Regulation has been quiet recently, but faster drug approvals are expected.
  • Faster approvals would aim to keep up with Chinese biotech momentum.
Ideas
Sean Laaman Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley 0:18
AI will transform drug development.
Morgan Stanley believes AI will change drug development more than any other sector, leading to better drugs reaching the market faster and more patient access to therapies. This is a positive structural thesis for biotechnology.
AI-SECTOR HIGH
Sean Laaman Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley 0:32
China biotech now genuine innovator.
China has become extremely dynamic in biotechnology, moving from fast follower to genuine innovator. There is a strong conference debate over whether China has taken the innovation mantle from the U.S., making China biotech a key positive and developing investment theme.
China biotechnology HIGH
Sean Laaman Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley 0:43
Faster drug approvals expected.
Although the regulatory environment has been quiet over the last six months, he expects faster passage of drugs to market as regulators try to keep up with China. This should benefit biotechnology by shortening development timelines and accelerating approvals.
XBI MED
Up Next
4:00
Fed Removed Dose of Accommodation With Hike, Chairman Warsh Says
Bloomberg Markets · Sep 16
32:33
Warsh Faces Markets and Trump
Bloomberg Markets · Sep 16
31:06
The CLARITY Act Failed - What Happens to Crypto Now?
Milk Road Macro · Sep 16
5:30
Rep. Josh Gottheimer: You can't get rid of data centers, but put them only where people want them
CNBC · Sep 16
2:30
U.S. dollar gets strong bid in reaction Fed's 25 bps rate hike
CNBC · Sep 16

This Morgan Stanley video, published September 16, 2026, features Sean Laaman discussing AI-SECTOR, China biotechnology, XBI. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Sean Laaman  · Tickers: AI-SECTOR, China biotechnology, XBI